Takeda said in September 2024 that it received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg, a selective oral inhibitor of ...
Weill Cornell Medicine researchers have determined the full-length structure of a blood pressure-regulating hormone receptor ...
In this trial, alisertib will be assessed in conjunction with endocrine therapy for treating individuals having hormone ...
Researchers elucidated the molecular details of how Drosophila larval epidermal cells (LECs) undergo cell death in a controlled manner to regulate epithelial tissue remodeling. Specifically, lower ...
Puma Biotechnology (PBYI) announced the initiation of its ALISertib in CAncer Phase II trial of alisertib in combination with endocrine therapy ...
News Medical on MSN9d
Vitamin D receptor activation slows cell overgrowth in pulmonary hypertensionThe study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...
News Medical on MSN4d
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapyResearchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...
Zacks.com on MSN15h
PBYI Begins Phase II Study on Alisertib Combo in Breast CancerPuma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback